Researcher
Nico Callewaert
- Keywords (Ghent University):medical biotechnology, protein engineering
- Disciplines (Flanders Institute for Biotechnology):Analytical biochemistry, Cell death and senescence, Analysis of next-generation sequence data, General diagnostics
- Disciplines (Ghent University):Infectious diseases, Proteins , Systems biology not elsewhere classified, Cell, tissue and organ engineering, Protein diagnostics , Medical biotechnology diagnostics , Medical molecular engineering of nucleic acids and proteins, Molecular biophysics, Microbiology not elsewhere classified, Immunology not elsewhere classified
Affiliations
- Department of Biomolecular Medicine (Department)
Member
From1 Oct 2018 → Today - VIB-UGent Center for Medical Biotechnology (Research Center)
Responsible
From1 Jan 2017 → Today - Callewaert Lab (Research group)
Responsible
From1 Jan 2017 → Today - Department of Biochemistry (Department)
Member
From1 May 2014 → 30 Sep 2018 - Department of Biochemistry and microbiology (Department)
Member
From1 Oct 2006 → Today - Department of Biomedical molecular biology (Department)
Member
From1 Oct 1998 → 30 Apr 2009
Projects
1 - 10 of 53
- Arming therapeutic CAR-T cells with glyco-engineered suppressors of tumor-infiltrating regulatory T cellsFrom1 Jan 2023 → Today
- Flow imaging microscope for advanced analysis of biopharmaceuticals and biological samplesFrom15 Dec 2022 → TodayFunding: BOF - scientific equipment program
- Development of a minimally-invasive test for accurate diagnosis of Cancer of Unknown Primary (CUP) using DNA methylation profilingFrom1 Oct 2021 → TodayFunding: BOF - projects
- A MALDI-8020 mass spectrometer for peptide and protein analysis.From1 Dec 2020 → 30 Nov 2022Funding: BOF - scientific equipment program
- Study of inducible glycome manipulation of CAR-T cells upon antigen exposure in the tumor environmentFrom1 Nov 2020 → TodayFunding: FWO fellowships
- Nanobody-based LYsosome TArgeting Chimeras (nanoLYTACs): development of a novel platform for lysosome-mediated targeted protein degradationFrom1 Nov 2020 → TodayFunding: FWO Strategic Basic Research Grant
- Understanding, optimizing and expanding target space of yeast-secreted, edible antibodies.From1 Nov 2020 → TodayFunding: FWO Strategic Basic Research Grant
- Development of inhaled anti-SARS-CoV-2 antibody.From1 Oct 2020 → 31 Dec 2022Funding: IOF - technology validation in lab
- Prophylaxis of at risks persons with an ultrapotent SARS-CoV-2-neutralizing antibodyFrom22 May 2020 → 31 May 2021Funding: FWO Special Call for Covid-19 research projects
- Enabling antibody prophylaxis of the elderly and vulnerable using yeast-based biotechnology.From15 Apr 2020 → 14 Jan 2021Funding: BOF - projects
Publications
1 - 10 of 133
- Validation of a glycomics-based test associated with risk of HCC development in cirrhosis(2022)Volume: 77
Authors: Xavier Verhelst, Leander Meuris, Roos Colman, Annelies Van Hecke, Anja Geerts, Nico Callewaert, Hans Van Vlierberghe
Pages: S913 - S913 - GENType : all-in-one preimplantation genetic testing by pedigree haplotyping and copy number profiling suitable for third-party reproduction(2022)
Authors: Lisa De Witte, Lennart Raman, Machteld Baetens, Andries De Koker, Nico Callewaert, Sofie Symoens, Kelly Tilleman, Frauke Vanden Meerschaut, Annelies Dheedene, Björn Menten
Pages: 1678 - 1691 - Yeast-produced fructosamine-3-kinase retains mobility after ex vivo intravitreal injection in human and bovine eyes as determined by Fluorescence Correlation Spectroscopy(2022)
Authors: An-Katrien Minnaert, Loes van Schie, Hendrik Grootaert, Jonas Himpe, Simon Devos, Wannes Weyts, Herlinde De Keersmaecker, Kevin Braeckmans, Elisabeth Van Aken, Joris Delanghe, et al.
- GlyConnect-Ugi : site-selective, multi-component glycoprotein conjugations through GlycoDelete expressed glycans(2022)
Authors: Karel Thooft, Wander Van Breedam, Francis Santens, Elise Wyseure, Sandrine Vanmarcke, Simon Devos, Nico Callewaert, Annemieke Madder
Pages: 464 - 471 - Pretransplant alterations in serum protein glycosylation are associated to risk of hcc recurrence after liver transplantation and provide a potential prognostic biomarker : a proof-of-concept study(2022)Volume: 106
Authors: Xavier Verhelst, Luis Abreu De Carvalho, Helena Degroote, Leander Meuris, Frederik Berrevoet, Nico Callewaert, Hans Van Vlierberghe
Pages: 20 - 20 - Pretransplant changes in serum protein glycosylation relate to risk of HCC recurrence after liver transplantation and provide a potential prognostic biomarker : a proof-of-concept study(2022)Volume: 77
Authors: Xavier Verhelst, Anja Geerts, Luis Abreu De Carvalho, Helena Degroote, Leander Meuris, Frederik Berrevoet, Nico Callewaert, Hans Van Vlierberghe
Pages: S768 - S768 - Engineering of yeast glycoprotein expression(2021)
Authors: Charlot De Wachter, Linde Van Landuyt, Nico Callewaert, Erdmann Rapp, Udo Reichl
Pages: 93 - 135 - A potential role for fructosamine-3-kinase in cataract treatment(2021)
Authors: Sander De Bruyne, Loes van Schie, Jonas Himpe, Filip De Somer, Inge Everaert, Wim Derave, Caroline Van den Broecke, Manon Huizing, Nezahat Bostan, Marijn Speeckaert, et al.
- T cell engaging immunotherapies, highlighting chimeric antigen receptor (CAR) T cell therapy(2021)
Authors: Elien De Bousser, Nico Callewaert, Nele Festjens
- FRI0304U+2005serum IGG-undergalactosylation profiles reflect cumulative exposure to systemic inflammation in spondyloarthritis patients(2021)Volume: 79
Authors: Ann-Sophie De Craemer, Z. Lukasik, L. Meuris, Liselotte Deroo, Thomas Renson, Manouk de Hooge, Philippe Carron, Annelies Van Hecke, Nico Callewaert, Filip Van den Bosch, et al.
Pages: 742.1 - 742